Oct 1, 2026 07:13AM
Aug 18, 2026 02:12AM
Jul 1, 2026 09:15AM
May 27, 2026 02:25AM
May 25, 2026 10:52PM
May 25, 2026 10:52PM
May 19, 2026 02:20AM Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Mar 26, 2026 03:19AM
Mar 4, 2026 06:25PM
Feb 18, 2026 02:28PM
Feb 11, 2026 01:29AM
Jan 22, 2026 07:38AM
Dec 19, 2025 02:43PM
Oct 30, 2025 02:16AM Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
Sep 24, 2025 02:07PM
Sep 24, 2025 02:06PM
Jul 17, 2025 01:43AM
Jul 17, 2025 01:43AM
Mar 21, 2025 10:15AM
Feb 6, 2025 01:34AM
Jan 7, 2025 11:19AM Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Dec 5, 2024 10:24AM
Oct 17, 2024 01:17AM
Jul 18, 2024 01:34AM
May 31, 2024 08:12AM
May 21, 2024 01:18AM
Feb 2, 2024 01:28AM
Dec 7, 2023 01:21AM Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
Jul 20, 2023 01:31AM
May 30, 2023 02:23AM
Mar 31, 2023 02:17AM
Nov 2, 2022 10:54PM
Oct 20, 2022 03:00AM
Jul 19, 2022 02:12AM
Jul 18, 2022 04:46PM Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform
May 30, 2022 11:06AM
Apr 21, 2022 02:38AM
Apr 7, 2022 02:17AM
Feb 3, 2022 02:17AM
Jan 9, 2022 11:52AM
Dec 29, 2021 02:14AM
Nov 15, 2021 02:41AM Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA
Oct 21, 2021 02:37AM
Apr 22, 2021 02:17AM
Apr 9, 2021 02:42AM
Apr 8, 2021 02:36AM
Jan 11, 2021 02:16AM
Oct 22, 2020 02:14AM
Sep 1, 2020 01:59PM Hansa Biopharma provides updated guidance on its clinical programs
Jul 16, 2020 02:20AM

334,171 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All